Psilocybin Clinical Trials: What Is Being Tested Right Now
Last reviewed
ClinicalTrials.gov lists 308 studies that match psilocybin as an intervention. 102 are recruiting now and 33 more are running but closed to new participants. This page picks out the ones most relevant to the questions people ask us, grouped by condition.
A registered trial is not a result. It tells you what researchers are testing, in how many people, and how far along it is. We link each trial to its registry record, and we say where we found published results.
How to read a trial listing
- Phase 1. A first look at safety and how the body handles it, usually in small groups.
- Phase 2. Early tests of whether it works, in larger groups, often with a comparison group.
- Phase 3. Large trials meant to confirm the result, and the kind regulators look at.
- Recruiting or active. Recruiting trials are still enrolling. Active, not recruiting means enrollment is closed and the study is running or being analyzed.
This is a selection, not the whole registry, and statuses change. We last checked every entry on October 28, 2026. To see everything, search the registry itself.
Depression
Depression has the largest and most advanced trials, including phase 3 trials that regulators will weigh. Our depression page covers what has been published so far.
- COMP360, two sessions, in treatment-resistant depression →
Phase 3 · Active, not recruiting · 572 people · NCT05711940
- Psilocybin for major depressive disorder →
Phase 3 · Active, not recruiting · 238 people · NCT06308653
- Psilocybin for veterans with treatment-resistant depression →
Phase 3 · Recruiting · 240 people · NCT07226232
- Psilocybin-assisted therapy for treatment-resistant depression in bipolar II disorder →
Phase 2 · Recruiting · 90 people · NCT06943573
Anxiety
Beyond the cancer-related trials on our anxiety page, a phase 2 trial is testing psilocybin in generalized anxiety disorder.
- Psilocybin oral solution in generalized anxiety disorder →
Phase 2 · Recruiting · 50 people · NCT06969170
PTSD
- COMP360 in PTSD (the Redefine study) →
Phase 2/3 · Recruiting · 300 people · NCT07570654
- Psilocybin-assisted therapy for PTSD →
Phase 2 · Recruiting · 150 people · NCT07332143
- Psilocybin for veterans and first responders with PTSD and alcohol use disorder →
Phase 2 · Active, not recruiting · 40 people · NCT06853912
Pain and headache
Pain trials are mostly small and early. None of the studies listed here has posted results. A five-person fibromyalgia pilot, which is not listed because it has finished, has been published and is on our chronic pain page.
- Psilocybin therapy for chronic low back pain →
Phase 1/2 · Active, not recruiting · 30 people · NCT05351541
- Psilocybin for chronic low back pain with depression →
Phase 1 · Recruiting · 40 people · NCT06355414
- Psilocybin for pain in fibromyalgia, against placebo →
Not applicable · Recruiting · 35 people · NCT06368492
- Psilocybin-assisted therapy for phantom limb pain →
Phase 1 · Active, not recruiting · 10 people · NCT05224336
- Psilocybin for chronic neuropathic pain →
Phase 2 · Recruiting · 30 people · NCT06731335
- Psilocybin for pain in advanced cancer →
Phase 2 · Active, not recruiting · 15 people · NCT06001749
- How psilocybin acts in migraine and other headache disorders →
Early phase 1 · Recruiting · 50 people · NCT06464367
Addiction
Our smoking page covers the published Johns Hopkins pilot. These are larger or newer trials for tobacco, opioids, and alcohol.
- Psilocybin for tobacco use disorder →
Phase 2 · Recruiting · 66 people · NCT05452772
- Psilocybin for opioid use disorder →
Phase 2 · Recruiting · 480 people · NCT06796062
- Psilocybin-assisted psychotherapy for alcohol use disorder →
Phase 2 · Recruiting · 128 people · NCT05995769
Microdosing
Only 9 of the psilocybin studies in the registry match a search for microdosing. These are the ones we found. Two have finished. Neither has posted results on the registry, and we could not confirm a published paper for either.
- Psilocybin microdose for distress in palliative care (placebo-controlled) →
Phase 3 · Recruiting · 120 people · NCT07063862
- Psilocybin microdosing with psychotherapy for treatment-resistant depression →
Phase 2 · Recruiting · 20 people · NCT07183748
- Psilocybin microdosing and cognition, mood, and quality of life →
Early phase 1 · Not yet recruiting · 20 people · NCT07449351
- Microdosing psychedelics to improve mood in major depression →
Phase 2 · Completed · 39 people · NCT05259943
- Naturalistic study of microdosing with psilocybin →
Not applicable · Completed · 34 people · NCT05160220
Whole mushrooms
Most trials use synthetic psilocybin made in a lab. A few are testing whole mushrooms. From their titles and summaries, none of them appears to compare a whole mushroom directly with synthetic psilocybin, which is still the open question on our research page.
- Organic whole psilocybin mushrooms for PTSD →
Phase 1 · Active, not recruiting · 24 people · NCT07275970
- Whole psilocybin mushroom for obsessive-compulsive disorder →
Phase 1 · Recruiting · 30 people · NCT07347405
- Whole Psilocybe cubensis mushrooms, with or without fluoxetine, for refractory depression →
Phase 1/2 · Recruiting · 24 people · NCT06898606
Music and setting
Our music page covers the small studies so far. This trial is testing it directly.
- The role of music in set and setting (PRoMiSS) →
Phase 1 · Recruiting · 100 people · NCT07180108
Keep reading
This page is for adults 21 and older. It summarizes published research for education only. It is not medical or legal advice, and it makes no claim that any product sold by Luna treats, cures, prevents, or helps any condition. Laws about these mushrooms vary by place, and you are responsible for knowing yours.
Research moves quickly. We last checked this page against its sources on , and we will correct it if we get something wrong.